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TCT-184
Immobilized recombinant human tropoelastin on a plasma-activated coating
dramatically enhances biocompatibility of metal alloys: implications for
coronary stents
Martin Ng1, 3, Anna Waterhouse3, Yongbai Yin2, Steven G Wise3, Daniel V Bax2,
David McKenzie2, Marcela Bilek2, Anthony S Weiss2
1Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; 2University of Sydney,
Sydney, Australia; 3Heart Research Institute, Sydney, Australia
Background: Metallic endovascular stents have suboptimal biocompatibility reducing
their clinical efficacy. We sought to develop a unique non-thrombogenic metal/protein
interface to covalently bind proteins in their bioactive state to metallic surfaces, to
achieve vascular biointegration of stents. We then bound recombinant human
tropoelastin (TE), a major regulator of vascular cells in vivo, and investigated the
biocompatibility of TE-coated metal compared to 316L stainless steel (SS).
Methods: A pulsed plasma deposition system was developed to deposit a plasma-
activated coating (PAC), a carbon-based surface capable of covalent protein binding,
on 316L stainless steel sheets or on slotted tube stents. Horseradish peroxidase and
human recombinant TE were bound to PAC. PAC surfaces were characterized for 1)
coating durability, 2) immobilized protein adhesion, activity and stability, 3) cellular
interactions and 4) thrombogenicity.
Results: PAC is extremely smooth (1-2nm rms roughness), is wear resistant using a 3
week pulsed flow of 500ml/min, 100pulses/min, and resists delamination after stent
expansion. Horseradish peroxidase activity (a probe for retention of protein
conformation) remained higher after 10 days when bound to PAC vs SS. TE remained
attached to PAC despite SDS washing, and incubation with supraphysiological serum
enzymes, indicating covalent binding. PAC+TE coating dramatically enhanced
endothelial cell attachment and proliferation by 86.3±10.5% (p<0.01) & 76.9±6.4%
(p<0.001 vs Control) respectively. Moreover, thrombus weight was reduced on PAC
& PAC+TE by 94.0±0.9% and 93±1.2% respectively (p<0.001 vs Control) in a
modified Chandler loop, and time to clot formation was reduced 3-fold. Serum soluble
P-selectin was reduced by 25.3±8.7% and 24.5±8.7% on PAC and PAC+TE
respectively, p<0.05.
Conclusion: PAC is durable, non-thrombogenic metal coating that enables covalent
binding of bioactive proteins to stents. PAC+TE enhanced endothelialisation and
remained non-thrombogenic. This has profound potential to improve stent efficacy.
TCT-185
Comparison of bivalirudin versus heparin during PCI in patients receiving
prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick,
Y Wang, GP Steg, E Deliargyris
Martial Hamon
CHU Caen, Caen, France
Background: Antiplatelet agents are used as adjunctive agents with BIV or
unfractionated or low molecular weight heparin (HEP) ± glycoprotein IIb/IIIa inhibitor
(GPI) in PCI. Prasugrel (PRAS) is a recently introduced agent and thus little data is
available regarding the use of PRAS with BIV.
Methods: Using the Premier Perspective database, 6986 patients who underwent
elective, urgent, or primary PCI between Q3 2009 and Q4 2010 from 166 US hospitals
were identified. Patients were treated with either BIV (n=3377) or HEP±GPI (n=3609)
on the day of PCI and given PRAS before or on the day of PCI. Outcomes of interest
included bleeding, transfusion, death, and hospital length of stay. To control for patient
and hospital level characteristics, propensity score matching analyses were performed.
Results: Outcomes are shown in the table.
Conclusion: In this analysis of real world data, patients receiving BIV and PRAS had
less bleeding than with HEP ± GPI and required less transfusion.
TCT-186
Combination Abciximab and t-PA Use with the Trellis™-6 Peripheral Infusion
System for Thrombotic Occlusion of the Superficial Femoral and Popliteal
Arteries
Eric J Dippel, Penny Stoakes, Desyree Weakley
Midwest Cardiovasular Research Foundation, Davenport, IA
Background: The Trellis™-6 (T6) catheter (Coviden, Mansfield, MA, USA) has
proximal and distal occlusion balloons with drug infusion holes inbetween and
mechanical drug dispersion capabilities allowing mechanical pharmacological
thrombolysis of the superficial femoral (SFA) and popliteal (Pop) arteries. Yet, the
optimal dose of lytics and ideal dwell time of the T6 catheter are unknown. We report
our experience with the combination abciximab (abc), t-PA and T6 in the SFA/Pop.
Methods: A retrospective review of our database of pts with thrombotic stent occlusion
(TSO) of the SFA/Pop and consecutively treated with the T6 catheter. The following
demographic variables were recorded: Age, Gender, Lesion length, Anti-thrombotic
tx, Anti-platelet tx, Thrombolytic tx, T6 dwell time, Adjunctive thrombo-embolic tx,
Pre/Post Hemoglobin (Hg), Bleeding complications, Length of stay (LOS).
Results: 15 patients met the above criteria. All patients received: clopidogrel 600mg
and aspirin 325mg pre-procedure; bivalirudin 0.75mg/kg IV bolus & 1.75mg/kg/hr
infusion IV for procedure duration; abc 0.25mg/kg bolus IA via T6, divided if multiple
dwells, & 10mcg/min IV x 12 hours; t-PA 10mg/30cm of T6 catheter with 10min dwell,
53% required 2 dwells for lesions >30cm. Age 72.4±9.3, Male 53%, Lesion length
37±11cm. The majority of the thrombus was lysed in all cases; adjunctive thrombo-
embolic tx was used in 53% of the cases to clean up minor residual thrombus. Pre Hg
13.0±1.9g/dL, Post Hg 10.9±2.2g/dL. A closure device was used in all cases. Bleeding
complications: 1 pt had a GI bleed, 3 pts had >4cm groin hematoma, 5 pts had
significant groin oozing, 3 pts had Hg drop > 3g/dL and received PRBC transfusion,
there were no intra-cranial bleeds. The average LOS was 1.7±1.3dys.
Conclusion: Combination of abc & t-PA delivered via the T6 catheter was efficacious
in minutes (compared to an overnight lytic infusion) for TSO of the SFA/Pop and
demonstrated moderate minor bleeding and occasional major bleeding. Comparative
studies of pharmacologic agents and dwell times are warranted.
TCT-187
The Utility and Safety of Bilivalirudin In the Out-Patient Peripheral
Procedures
R. Stefan Kiesz1, Magda D Konkolewska1, Szymon L Wiernek2, Barbara K Wiernek2,
Radoslaw J Szymanski2, Pawel E Buszman2
1San Antonio Endovascular & Heart Institute, San Antonio, TX; 2American Heart of
Poland, Katowice, Poland
Background: According to recent studies Bivalirudin, in comparison to heparin,
provides reduced clinical event rates after percutaneous coronary interventions. In
peripheral interventions it is even more important to obtain a predictable and reliable
anticoagulation level because of the higher risk of the vascular and bleeding
complications. Therefore, and in the light of increasing demands for health care cost
reduction, we believe that by combining Bivalirudin with Vascular Closure Device
(VCD), we can safely discharge patients within 5 hours after the procedure. The aim
of this study was to evaluate the incidence of early and late complication rates after
the same-day discharge peripheral intervention with the use of Bivalirudin as the
procedural anticoagulant.
Methods: Between January 2008 and May 2011, in San Antonio Endovascular & Heart
Institute 409 peripheral interventions were performed in 188 consecutive patients.
Patients received Bivalirudin in accordance with the standard protocol. Hemostasis
was obtained with Mynx VCD. Primary end point (Major Vascular Complications):
retroperoneal bleeding, urgent hospitalization, hematoma>5cm and pseudoaneurysm.
Secondary end point (Minor Vascular Complications): ecchymosis, hematoma <5cm
and adjunctive manual compression. Follow up was performed three times: before
discharge, next day and 30 (±5) days after the procedure.
Results: 168 procedures (41.1%) were performed with antegrade approach. Hemostasis
was achieved after 409 (100%) procedures. Mean times to hemostatsis and ambulation
were 2.5+/-3.9 min and 3.1+/-2.8 hours, respectively. All patients were discharged on
the day of intervention. Primary end points noted in 16 cases (3.9%) included 7
hematomas>5cm, 3 retroperoneal bleedings, 2 pseudoaneurysms and 4 hospitalizations.
Secondary end point was observed after 61 (14.9%) procedures (19 hematomas<5cm,
4 adjunctive manual compressions, 38 ecchymosis<20cm).
Conclusion: Bivalirudin, thanks to favorable pharmacokinetics and
pharmacodynamics, is an attractive alternative to heparin in Peripheral Interventions
and seems to ensure safe discharge 5 hours after the procedure.
TCT-188
Long Term Outcomes in Patients with Acetylsalicylic Acid Sensitivity
Undergoing a Novel Desensitization Protocol
Roberta Rossini1, Giuseppe Musumeci1, Laurian Mihalcsik1, Ana Inashvili1, Vasile
Sirbu1, Davide Capodanno2, Nikoloz Lordkipanidze1, Orazio Valsecchi1, Giulio
Guagliumi1, Dominick J Angiolillo3, Antonello Gavazzi1
1Cardiovascular Dpt, Ospedali Riuniti di Bergamo, Bergamo, Italy; 2Università di
Catania, Catania, Italy; 3University of Florida-Shands Jacksonville, Jacksonville,
FL
Background: Some patients (pts) are unable to tolerate apirin due to sensitivity,
precluding them from the benefits of this therapy. The aim of this study was to test the
safety and efficacy of a new standard desensitization procedure, using escalating low
doses of aspirin in pts with acetylsalicylic acid sensitivity.
Methods: Out of 3080 pts undergoing coronary angiography, seventy-seven had a
history of aspirin sensitivity (2.5%). They were admitted for acute coronary syndrome
(67.2%) or stable angina (32.8%). A history of cutaneous reactions was reported in
76% of pts, respiratory sensitivity in 21.5%, whereas 2.5% had a history of anaphylactic
shock. All pts underwent the desensitization procedure: six sequential doses of aspirin
(1, 5, 10, 20, 40, and 100 mg) administered orally at predefined intervals, with the
procedure lasting 5.5 hours. None received pretreatment with antihistamines or
corticosteroids, and beta-blockers were withheld 24 hours before desensitization. Blood
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pressure, pulse, cutaneous, nasoocular, or pulmonary reactions were monitored until 4
hours after the procedure. Pts were followed-up for 18.1± 6.3 months. Major adverse
cardiac events (MACE), defined as death, repeat revascularization and stroke were
recorded.
Results: The desensitization procedure was successful in 71 pts (92.2%). No serious
adverse reactions occurred: 3 pts with history of idiopathic urticaria developed
cutaneous reaction, 2 pts (with frequent asthma attacks) experienced shortness of breath
associated with bronchospasm, and 1 pt had shortness of breath without bronchospasm.
All reactions were immediately resolved with corticosteroids and antihistamines. The
mean time from desensitization to coronary angiography was 35.6±33.3 hours. All pts
but 15 (19.4%) underwent PCI (1.8 stent/pt, DES 75.5%, multivessel PCI 31.4%) and
were discharged on dual antiplatelet therapy. At follow-up, aspirin was maintained in
92.9% pts. None of the discontinuations were due to allergic reaction. The incidence
of MACE was 6.5% (1 non-cardiac death and 4 repeat revascularizations). None of
the pts experienced stent thrombosis.
Conclusion: This novel desensitization procedure seems to be safe and effective in
the vast majority of pts with cutaneous or respiratory aspirin sensitivity. Complex PCI
procedures can be performed also in such pts, without increasing the risk of stent
thrombosis.
Bioabsorbable, Drug-Eluting, and Bare Metal Stent
Studies 
(Abstract nos 192 - 268)
TCT-192
Two-Year Patient Outcomes with the Resolute Zotarolimus-Eluting Stent:
Results of the RESOLUTE International Registry
Jorge Belardi1, Franz-Josef Neumann2, Petr Widimsky3
1Instituto Cardiovascular de Buenos Aires, Buenos Aires, Brazil; 2Heart Center Bad
Krozingen, Bad Krozingen, Germany; 3University Hospital Kralovské Vinohrady,
Prague, Czech Republic
Background: The Resolute stent (R-ZES) is a new-generation zotarolimus-eluting
stent that utilizes the BioLinx polymer, a proprietary tri-polymer coating that provides
gradual drug elution out to 180 days while maintaining biocompatibility to allow for
neointimal healing. The RESOLUTE International study showed optimal 1-year
performance of the R-ZES for treatment of coronary artery disease, however, longer
follow-up is required for a full comprehension of its clinical safety and efficacy.
Methods: RESOLUTE International is part of the Global RESOLUTE Clinical Trial
Program, and is a prospective, multi-center, observational registry, which enrolled 2349
patients with symptomatic coronary artery disease from 88 centers worldwide. The
trial had minimal eligibility criteria to reflect routine clinical practice, and the primary
endpoint was cardiac death and target-vessel myocardial infarction (CD/TV-MI) at 1
year. This trial was harmonized with the rest of the Global RESOLUTE Clinical
Program from an adjudication point of view. Enhanced edit checks to detect unreported
procedural MIs; and full monitoring of all patient consents and 25% monitoring of
patient source files were also per performed. We will report the overall 2-year clinical
outcomes, and comparisons between unmonitored (75%) and source file monitored
(25%) patient cohorts.
Results: Patients were enrolled between 29 August 2008 and 19 March 2009, and
97.4% of patients completed 1-yr follow-up. At baseline, 78% were male, 31% had
diabetes mellitus, 46% with acute coronary syndrome, and 67.5% had at least 1
complex clinical/lesion characteristic. . Clinical outcomes at 1 year were; CD/TV-MI,
4.2%; TLR, 3.4%; and definite/probable ST, 0.9%. There were no significant
differences in 1-year outcomes between monitored and unmonitored patients, reflecting
the robustness of the trial data.
Conclusion: We will report the overall 2-year clinical outcomes with special emphasis
on safety endpoints at the time of the meeting.
TCT-193
Outcomes After Revascularization with Everolimus- and Sirolimus Eluting
Stents In Patients with Acute Coronary Syndromes. A Substudy of the SORT
OUT IV Trial
Lisbeth Antonsen1, Per Thayssen1, Henrik Steen Hansen1, Michael Maeng2, Hans-
Henrik Tilsted3, Evald Hoej Christiansen2, Knud Noerregaard Hansen1, Hans Erik
Boetker2, Jan Ravkilde3, Lars Krusell2, Morten Madsen4, Henrik Toft Soerensen4,
Leif Thuesen2, Jens Flensted Lassen2, Lisette Okkels Jensen1
1Department of Cardiology, Odense University Hospital, Odense, Denmark;
2Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark;
3Department of Cardiology, Aarhus University Hospital, Aalborg, Denmark;
4Department of Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background: Randomized trials comparing outcomes after implantation of first
generation drug-eluting stents (DES) versus second generation DESs in patients with
acute coronary syndromes (ACS) are limited. In this substudy of the SORT OUT IV
trial, we compared the clinical outcome among patients with ACS and stable angina
pectoris (SAP) treated with everolimus-eluting stents (EES) or sirolimus-eluting stents
(SES).
Methods: Of 2,705 patients treated for ACS or SAP, 1,178 (43.5%) patients had ACS
and were treated with EES (n=1,353, ACS: n=580) or SES (n=1,352, ACS: n=598).
The primary composite endpoint, major adverse cardiac events (MACE), was defined
as a composite of cardiac death, myocardial infarction (MI), stent thrombosis, or target
vessel revascularization (TVR) within 18 months.
Results: 18-month MACE was higher among ACS patients compared to patients with
SAP: 8.1% vs. 6.7%, Hazard Ratio (HR) 1.23, 95 % confidence interval (CI) 0.93-
1.62. In ACS patients, clinical outcome in EES treated patients did not differ
significantly to SES treated patients at 18 months; MACE 7.3% vs. 8.9% (HR 0.81,
95% CI 0.54-1.22), cardiac death 2.8% vs. 2.0% (HR 1.39, 95% CI 0.66-2.93), MI
2.1% vs. 2.3% (HR 0.88, 95% CI 0.41-1.91), stent thrombosis 0.5% vs. 0.7% (HR
0.77, 95% CI 0.17-3.45) and TVR 4.3% vs. 5.9%, (HR 0.73, 95% CI 0.44-1.22). Also
in patients with SAP, the clinical outcome did not differ significantly between EES-
and SES-treated patients.
Conclusion: EES and SES appear similar with respect to MACE in patients with ACS.
TCT-194
Off-Label Use of Drug Eluting Stent with Biodegradable Polymer at 2 Years
Gian Battista Danzi1, William Wijns2, Zoran Perisic3, Francisco Bossa4, René
Koning5, Petr Kala6, Farzin Fath-Oroubadhi7, Didier Carrie8, Luciano Moretti9, Kai
Oppenländer10, Emanuele Barbato2
1Ospedale Maggiore Policlinico, Milan, Italy; 2Cardiovascular Center OLV
Hospital, Aalst, Belgium; 3University Clinical Center Nis, Nis, Serbia; 4Hospital
Universitario de Canarias, Tenerife, Spain; 5Clinique Saint-Hilaire, Rouen, France;
6University Hospital, Brno, Czech Republic; 7Manchester Royal Infirmary,
Manchester, United Kingdom; 8CHU de Toulouse - Hopital de Rangueil, Toulouse,
France; 9Ospedale C.G. Mazzoni, Ascoli Piceno, Italy; 10St. Elisabeth Klinik,
Saarlouis, Germany
Background: Nobori drug eluting stent (DES) is coated only abluminally with a matrix
of drug Biolimus A9 and polymer degradable within 1 year. We explored the safety
benefit of the DES after full polymer degradation particularly in high risk patient
populations.
Methods: NOBORI2 study enrolled 3067 consecutive patients in 125 centers in
Europe and Asia treated with Nobori DES. Patients were assigned to one of the pre-
specified groups: On-label and Off-label groups. The Off-label group was composed
of patients mainly outside of the indications proven in pivotal trials. Primary endpoint
was target lesion failure (TLF), a composite of cardiac death, MI and target lesion
revascularization (TLR) at 1 year. Data are monitored through electronic database and
on-site. All adverse events are adjudicated by an independent clinical event committee
and an independent corelab analyzes angiographic images.
Results: In this real-world population 73% of patients were treated for Off-label
indications. The most frequent Off-label indications were acute coronary syndrome
(65%), bifurcation stenting (26%), occlusion (12%), restenosis (9%) and saphenous
vein graft (2%). Patients in Off-label use were more frequently male, had higher
incidence of moderate to severe renal impairment and history of MI. Lesions in Off-
label group were more complex, more frequently ostial, thrombotic and calcified
(p<0.005). At 2 year follow-up 94.7% of patients were contacted; the TLF rate was
5.9% (132 pts) in Off-label group and 2.8% (23 pts) in On-label group (p<0.001). In
Off-label group 1.9% of patients died of cardiac cause, 2.7% suffered MI and 2.4%
underwent re-PCI of the target lesion. In On-label group 0.7% of patients died, 1.5%
suffered MI and 0.6% underwent re-PCI of the target lesion. Stent thrombosis rate was
0.9% in Off- and 0.6% in On-label treated patients (p=NS).
Conclusion: Low rates of TLF and late stent thrombosis at 2 years follow-up for
patients treated for Off-Label indications are very encouraging. They further indicate
the potential benefit of Nobori DES even for treatment of challenging lesions and high-
risk patients with coronary artery disease.
TCT-195
Current Treatment and Outcome of Coronary In-Stent Restenosis – Report
from the Swedish Angiography and Angioplasty Registry (SCAAR)
Torsten Schwalm1, Jörg Carlsson1, Bo Lagerqvist2, Stefan James2
1Interventional Cardiology, Kalmar County Hospital, Kalmar, Sweden; 2Uppsala
Clinical Research Center, Uppsala, Sweden
Background: We used the Swedish angiography and angioplasty registry (SCAAR)
to investigate occurrence and results of treatment of in - stent restenosis (ISR) in
coronary stents.
Methods: We evaluated clinically driven results of treatment of ISR in a very large
patient cohort of all consecutive coronary stent implantations in Sweden between
January 1, 2005 and October 06, 2010. The data were analyzed with regard to different
types of treatment, patient and stenosis characteristics. 142678 stents were implanted
during the time period, of these 9031 were implanted in ISR at 7134 procedures in
6191 patients.
Results: 1. Through the years 2005 (4.3%) till 2010 (6.1%) occurrence of PCI - treated
ISR has not decreased. 2. Direct DES - stenting shows a reported re - restenosis rate
of 3.8 % at 1 year. Also with DEB - therapy the rate at 1 year was low (4.8 %) but on
a still low number of patients. Re – restenosis rate after direct BMS – stenting (7.4 %)
B51JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Bioabsorbable, Drug-Eluting, and Bare Metal Stent Studies
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
